Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patients Oakville, Ontario–(Newsfile Corp. – August 3, 2022) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol”...
Oakville, Ontario–(Newsfile Corp. – June 29, 2022) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on...
Oakville, Ontario–(Newsfile Corp. – June 27, 2022) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on...
Oakville, Ontario–(Newsfile Corp. – June 9, 2022) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on...
Oakville, Ontario–(Newsfile Corp. – May 19, 2022) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on...
Third IND authorization for CardiolRx™ in cardiovascular disease Study to run in parallel with Company’s multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™...
Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19 Received authorization from...
Oakville, Ontario–(Newsfile Corp. – March 22, 2022) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on...
Oakville, Ontario–(Newsfile Corp. – March 15, 2022) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on...
LANCER Trial expanded to include up to 20 Additional Clinical Research Centers Oakville, Ontario–(Newsfile Corp. – March 1, 2022) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX:...